Thalidomide and Lenalidomide for Refractory SLE/CLE Thalidomide and Lenalidomide for Refractory SLE/CLE
What do we currently know about the safety and efficacy of these drug options for the treatment of refractory systemic/cutaneous lupus erythematosus?Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Biocon inks patent litigation settlement pact with Celgene
The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide), the Bengaluru-based company said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 8, 2021 Category: Pharmaceuticals Source Type: news

Dr Reddy's launches cancer drug in Canada
"Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada's Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population," Vinod Ramachandran, Vice President and General Manager, Dr. Reddy's Laboratories Canada said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 2, 2021 Category: Pharmaceuticals Source Type: news

Sun Pharma settles patent litigation with Celgene Corporation for cancer drug Revlimid
Drug major Sun Pharma has reached an agreement with Celgene Corporation, to resolve the patent litigation regarding generic version of Revlimid (lenalidomide capsules) in the US. Revlimid is used in the treatment of cancer. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 22, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlight...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Natco Pharma gets American drug regulator's nod for generic cancer treatment drug
Natco, along with its marketing partner Arrow International previously settled the Paragraph IV litigation related to the product with Celgene, now part of Bristol-Myers Squibb, who sells the product under the brand name 'Revlimid', it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2021 Category: Pharmaceuticals Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
Progression - free, three - year overall survival similar for lenalidomide maintenance regimen without dexamethasone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 24, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
WEDNESDAY, March 24, 2021 -- Dose/schedule-adjusted lenalidomide-dexamethasone (Rd) followed by a maintenance regimen of lenalidomide 10 mg/day without dexamethasone (Rd-R) is feasible for older patients with multiple myeloma (MM), with survival... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2021 Category: Pharmaceuticals Source Type: news

Medication-based starvation of cancer cells
(Technical University of Munich (TUM)) Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide have significantly improved the therapy of hematologic malignancies such as multiple myeloma. Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action in this class of medications. At the same time, they identified new innovative targeted cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2021 Category: Cancer & Oncology Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Informe actualizado sobre la seguridad del medicamento Revlimid (lenalidomida) para el c áncer y el riesgo de nuevos tipos de neoplasias (nuevos tipos de cáncer)
El 7 de mayo del 2012, la Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público sobre el aumento en el riesgo de segundas neoplasias primarias (nuevos tipos de cáncer) en pacientes con mieloma múltiple de reciente diagnóstico, que tomaron Revlimid (lenalidomida). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 29, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Cleveland Clinic receives two grants totaling $4.6m to study cancer drug in Alzheimer's
(Cleveland Clinic) The National Institute of Aging (NIA), part of the National Institutes of Health (NIH), and the Alzheimer's Drug Discovery Foundation (ADDF) awarded five-year grants of $3.2 million and $1.4 million, respectively, to scientists from Cleveland Clinic Lou Ruvo Center for Brain Health to study the therapeutic potential of the anti-cancer drug lenalidomide in early-stage Alzheimer's disease, known as mild cognitive impairment (MCI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 27, 2021 Category: International Medicine & Public Health Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

RVD Induction Therapy in Newly Diagnosed Multiple Myeloma RVD Induction Therapy in Newly Diagnosed Multiple Myeloma
What benefits might be achieved with a combination lenalidomide, bortezomib, and dexamethasone induction regimen in patients with multiple myeloma?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA Approves New Drug for Diffuse Large B-Cell Lymphoma FDA Approves New Drug for Diffuse Large B-Cell Lymphoma
A novel drug that targets CD19 has been approved for use with lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

NHS England spends £160m on new 'Covid-friendly' cancer drugs
Patients to be given treatments less likely to damage immune system and in some cases able to be taken at homeNHS England is spending £160m on new “Covid-friendly” cancer drugs that will be less likely to damage the immune system and, in some cases, can be taken at home so that patients do not have to visit hospital.NHS England said 2,000 patients had already benefitted from a range of treatments approved for use as “swaps” for existing drugs. More will be available from this week, after a series of deals struck between the NHS and pharma companies, it said in a statement.Some of these new opt...
Source: Guardian Unlimited Science - August 2, 2020 Category: Science Authors: Sarah Boseley Health editor Tags: NHS Cancer Society Health Cancer research Medical research Science UK news Coronavirus outbreak Source Type: news

FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
PLANEGG/MUNICH, Germany - August 1, 2020 and WILMINGTON, Del. - July 31, 2020 MorphoSys AG NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) in combination... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

Natco Pharma's Canadian unit signs pact with Celgene for cancer treatment drug
Natco Pharma entered into an agreement with biopharmaceutical firm Celgene for Lenalidomide capsules, which is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 9, 2020 Category: Pharmaceuticals Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma
Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Parameswaran Hari, MD, MRCP Source Type: news

Carfilzomib Triplet Therapy Shows Inferior PFS in Newly Diagnosed Multiple Myeloma
Carfilzomib combined with lenalidomide and dexamethasone failed to improve progression-free survival, compared with the current standard of care triplet of bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Jessica Skarzynski Source Type: news

Carfilzomib does not improve outcomes in newly diagnosed myeloma compared to bortezomib
(ECOG-ACRIN Cancer Research Group) The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not improve progression-free survival in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care -- bortezomib, lenalidomide, and dexamethasone (VRd). The data from a planned interim analysis for the ENDURANCE (E1A11) randomized phase three trial will be presented at the ASCO 2020 plenary. KRd had more severe cardiac, pulmonary, and renal toxicities. Neuropathy was more common among those receiving VRd. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 28, 2020 Category: International Medicine & Public Health Source Type: news

FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
FDA approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Isatuximab Combination for Previously Treated Multiple Myeloma
The FDA approved isatuximab-irfc, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - March 2, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Tafasitamab/Lenalidomide Combination for DLBCL
The FDA granted priority review to a biologics license application for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - March 2, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Hundreds of lymphoma patients are set to benefit from the first chemotherapy-free treatment
Drugs watchdog NICE today approves NHS use of cutting-edge drug lenalidomide, which will benefit an estimated 900 cancer patients in England. (Source: the Mail online | Health)
Source: the Mail online | Health - February 27, 2020 Category: Consumer Health News Source Type: news

Peter Voorhees, MD, Discusses Results from the Ongoing GRIFFIN Study
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Peter Voorhees, MD Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

Combination Therapy Induces High Response Among Relapsed/Refractory Follicular Lymphoma
The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Featured Review: Reducing uncertainties in choosing first-line treatment in newly diagnosed multiple myeloma
Multiple myeloma is a type of blood cancer. It accounts for approximately 2% of all cancers and is still considered incurable. For people with newly diagnosed multiple myeloma (NDMM), who are unsuitable for a procedure where damaged blood cells are replaced with healthy ones (stem-cell transplant), treatment is usually a multiple drug combination of bortezomib, lenalidomide, or thalidomide, plus melphalan and prednisolone (MP) or dexamethasone (D). Multiple drug combinations are approved for initial anti-myeloma therapy, however, access to these medicines is restricted in many countries worldwide.The Cochrane Review used n...
Source: Cochrane News and Events - November 26, 2019 Category: Information Technology Authors: Katie Abbotts Source Type: news

Lenalidomide Slows Progression of Smoldering Multiple Myeloma Lenalidomide Slows Progression of Smoldering Multiple Myeloma
Early treatment with lenalidomide significantly delays the progression of smoldering multiple myeloma to symptomatic disease, according to the results of a randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 23, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Lenalidomide Delays Progression in Smoldering Multiple Myeloma
THURSDAY, Nov. 7, 2019 -- Lenalidomide significantly delays progression to symptomatic multiple myeloma in patients with smoldering multiple myeloma, according to a study published online Oct. 25 in the Journal of Clinical Oncology. Sagar Lonial,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2019 Category: Pharmaceuticals Source Type: news

Smoldering Multiple Myeloma Can Be Slowed by Lenalidomide
Early treatment with lenalidomide can stave off multiple myeloma and provide longer progression-free survival (PFS) than just monitoring alone. (Source: CancerNetwork)
Source: CancerNetwork - October 29, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Lenalidomide may delay onset of myeloma-related bone, organ damage
ROCHESTER Minn. -- The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute, were published Friday, Oct. [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - October 25, 2019 Category: Research Source Type: news

lenalidomide (Revlimid)
Title: lenalidomide (Revlimid)Category: MedicationsCreated: 3/25/2015 12:00:00 AMLast Editorial Review: 8/22/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 22, 2019 Category: Cancer & Oncology Source Type: news

Promising New Combo Found For DLBCL
A combination of ibrutinib, lenalidomide, and rituximab was tested on patients with  relapsed or refractory diffuse large B-cell lymphoma, particularly those with non-GCB subtype. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

GALEN Study Examines Lenalidomide, Obinutuzumab Combo in Follicular Lymphoma
In this phase II GALEN study, researchers examined the effects of lenalidomide and obinutuzumab in patients with relapsed or refractory follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - July 16, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

FDA Approves Daratumumab Combination For Multiple Myeloma
The FDA approved daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2019 Category: Cancer & Oncology Authors: Erin Kayata Source Type: news

Janssen Announces U.S. FDA Approval of DARZALEX ® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 27, 2019 Category: Pharmaceuticals Source Type: news

Janssen Announces FDA Approval of Darzalex (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
HORSHAM, Pa., June 27, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 27, 2019 Category: Drugs & Pharmacology Source Type: news

Could Lenalidomide Be a New Standard for High-Risk Smoldering Myeloma?
Results from a second clinical trial examined the use of lenalidomide treatment in patients with high-risk smoldering multiple myeloma, where the standard of care has been observation. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
(University of Texas M. D. Anderson Cancer Center) Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2019 Category: International Medicine & Public Health Source Type: news

Lenalidomide/Anti-CD19 Antibody Combo Yields Encouraging Results in Poor-Prognosis DLBCL
Researchers studied the Fc-enhanced, humanized anti-CD19 antibody MOR208 combined with lenalidomide in  relapsed/refractory large B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lenalidomide + Rituximab Beneficial in Relapsed/Refractory Non-Hodgkin Lymphoma
The MAGNIFY phase IIIb trial looked at the efficacy and safety of lenalidomide combined with rituximab in  relapsed/refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Daratumumab Triplet for First-Line Myeloma, but Questions Remain Daratumumab Triplet for First-Line Myeloma, but Questions Remain
The daratumumab, lenalidomide, and dexamethasone triplet is a new frontline option for patients with multiple myeloma who are not candidates for transplant, but how practice-changing are the data?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 29, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Daratumumab Cuts Risk for Progression in Multiple Myeloma
WEDNESDAY, May 29, 2019 -- For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 29, 2019 Category: Pharmaceuticals Source Type: news